iTeos Therapeutics, Inc. (NASDAQ:ITOS) CFO Matthew Gall Buys 5,000 Shares

iTeos Therapeutics, Inc. (NASDAQ:ITOS) CFO Matthew Gall bought 5,000 shares of the stock in a transaction on Tuesday, November 19th. The stock was purchased at an average cost of $7.73 per share, with a total value of $38,650.00. Following the completion of the purchase, the chief financial officer now directly owns 65,429 shares in the company, valued at $505,766.17. This trade represents a 8.27 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

iTeos Therapeutics Stock Performance

NASDAQ:ITOS opened at $7.85 on Thursday. The firm’s fifty day simple moving average is $9.79 and its 200 day simple moving average is $13.91. iTeos Therapeutics, Inc. has a twelve month low of $7.66 and a twelve month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. Sell-side analysts anticipate that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research note on Tuesday, November 12th. JPMorgan Chase & Co. lowered their price objective on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Wells Fargo & Company assumed coverage on shares of iTeos Therapeutics in a research note on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $46.00 price objective on shares of iTeos Therapeutics in a research note on Friday, November 15th.

Hedge Funds Weigh In On iTeos Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in shares of iTeos Therapeutics in the 1st quarter valued at about $3,337,000. Clearline Capital LP acquired a new stake in shares of iTeos Therapeutics in the 2nd quarter valued at about $2,328,000. Candriam S.C.A. acquired a new stake in shares of iTeos Therapeutics in the 2nd quarter valued at about $7,558,000. Kennedy Capital Management LLC acquired a new stake in shares of iTeos Therapeutics in the 1st quarter valued at about $1,988,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of iTeos Therapeutics by 14.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after purchasing an additional 117,159 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.